Zhang Di, Chai Yue, Wei Yuce, Qi Fei, Dong Mei
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.
Head Neck. 2022 Nov;44(11):2407-2416. doi: 10.1002/hed.27143. Epub 2022 Jul 13.
To investigate the clinical characteristics, treatment, and prognosis of patients with metastatic head and neck adenoid cystic carcinoma (HNACC).
The clinical data of metastatic HNACC from 1999 to 2020 at the National Cancer Center of China were retrospectively collected.
One hundred seventy-four patients with metastatic HNACC were enrolled and median overall survival (OS) was 45.6 months. Univariate analysis indicated that smoking history, disease-free interval (DFI), number and sites of metastases, and systemic therapy were associated with OS. In the multivariate analysis, non-smokers, DFI ≥3 years, and lung metastasis were prognostic factors. Local therapy for localized disease could prolong survival in patients with both recurrent and metastatic disease.
No smoking history, DFI ≥3 years, and lung metastasis were favorable prognostic factors. Local therapy for metastases could not provide survival benefits, but local therapy for localized disease may prolong survival. Whether initial systemic therapy could improve prognosis needs further exploration.
探讨转移性头颈部腺样囊性癌（HNACC）患者的临床特征、治疗方法及预后。
回顾性收集1999年至2020年中国国家癌症中心转移性HNACC的临床资料。
纳入174例转移性HNACC患者，中位总生存期（OS）为45.6个月。单因素分析表明，吸烟史、无病生存期（DFI）、转移灶数量和部位以及全身治疗与OS相关。多因素分析显示，不吸烟者、DFI≥3年和肺转移是预后因素。针对局限性疾病的局部治疗可延长复发和转移性疾病患者的生存期。
无吸烟史、DFI≥3年和肺转移是有利的预后因素。针对转移灶的局部治疗不能带来生存获益，但针对局限性疾病的局部治疗可能延长生存期。初始全身治疗能否改善预后有待进一步探索。
